Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 2
1987 3
1988 2
1989 2
1990 3
1991 5
1992 3
1993 3
1994 6
1995 9
1996 1
1997 2
1998 8
1999 4
2000 6
2001 5
2002 3
2003 2
2004 4
2006 6
2007 2
2008 2
2009 2
2010 8
2011 5
2012 4
2013 3
2014 4
2015 5
2016 1
2017 1
2018 2
2019 3
2020 2
2021 1
Text availability
Article attribute
Article type
Publication date

Search Results

118 results
Results by year
Filters applied: . Clear all
Page 1
Caffeine, creatine, GRIN2A and Parkinson's disease progression.
Simon DK, Wu C, Tilley BC, Lohmann K, Klein C, Payami H, Wills AM, Aminoff MJ, Bainbridge J, Dewey R, Hauser RA, Schaake S, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wei P, Wong PS, Yang T. Simon DK, et al. Among authors: schneider js. J Neurol Sci. 2017 Apr 15;375:355-359. doi: 10.1016/j.jns.2017.02.032. Epub 2017 Feb 17. J Neurol Sci. 2017. PMID: 28320167 Free PMC article.
Caffeine is neuroprotective in animal models of Parkinson's disease (PD) and caffeine intake is inversely associated with the risk of PD. ...
Caffeine is neuroprotective in animal models of Parkinson's disease (PD) and caffeine intake is inversely associated wi …
Gangliosides: Treatment Avenues in Neurodegenerative Disease.
Magistretti PJ, Geisler FH, Schneider JS, Li PA, Fiumelli H, Sipione S. Magistretti PJ, et al. Among authors: schneider js. Front Neurol. 2019 Aug 6;10:859. doi: 10.3389/fneur.2019.00859. eCollection 2019. Front Neurol. 2019. PMID: 31447771 Free PMC article. Review.
There is level-I evidence from 5 RCTs of a significantly faster recovery with GM1 vs. placebo in patients with acute and chronic spinal cord injury (SCI), disturbance of consciousness after subarachnoid hemorrhage, or craniocerebral injuries due to closed head trauma. In Parki
There is level-I evidence from 5 RCTs of a significantly faster recovery with GM1 vs. placebo in patients with acute and chronic spinal cord …
Caffeine and Progression of Parkinson Disease: A Deleterious Interaction With Creatine.
Simon DK, Wu C, Tilley BC, Wills AM, Aminoff MJ, Bainbridge J, Hauser RA, Schneider JS, Sharma S, Singer C, Tanner CM, Truong D, Wong PS. Simon DK, et al. Among authors: schneider js. Clin Neuropharmacol. 2015 Sep-Oct;38(5):163-9. doi: 10.1097/WNF.0000000000000102. Clin Neuropharmacol. 2015. PMID: 26366971 Free PMC article. Clinical Trial.
OBJECTIVE: Increased caffeine intake is associated with a lower risk of Parkinson disease (PD) and is neuroprotective in mouse models of PD. ...The association of caffeine intake with rate of progression of PD as measured by the change in the total Unified Parkin
OBJECTIVE: Increased caffeine intake is associated with a lower risk of Parkinson disease (PD) and is neuroprotective in mouse …
Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial.
Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, Kieburtz K, Tilley BC, Elm JJ, Babcock D, Hauser R, Ross GW, Augustine AH, Augustine EU, Aminoff MJ, Bodis-Wollner IG, Boyd J, Cambi F, Chou K, Christine CW, Cines M, Dahodwala N, Derwent L, Dewey RB Jr, Hawthorne K, Houghton DJ, Kamp C, Leehey M, Lew MF, Liang GS, Luo ST, Mari Z, Morgan JC, Parashos S, Pérez A, Petrovitch H, Rajan S, Reichwein S, Roth JT, Schneider JS, Shannon KM, Simon DK, Simuni T, Singer C, Sudarsky L, Tanner CM, Umeh CC, Williams K, Wills AM. Writing Group for the NINDS Exploratory Trials in Parkinson Disease (NET-PD) Investigators, et al. Among authors: schneider js. JAMA. 2015 Feb 10;313(6):584-93. doi: 10.1001/jama.2015.120. JAMA. 2015. PMID: 25668262 Free PMC article. Clinical Trial.
IMPORTANCE: There are no treatments available to slow or prevent the progression of Parkinson disease, despite its global prevalence and significant health care burden. The National Institute of Neurological Disorders and Stroke Exploratory Trials in Parki
IMPORTANCE: There are no treatments available to slow or prevent the progression of Parkinson disease, despite its global prev …
A novel dopamine D3R agonist SK609 with norepinephrine transporter inhibition promotes improvement in cognitive task performance in rodent and non-human primate models of Parkinson's disease.
Schneider JS, Marshall CA, Keibel L, Snyder NW, Hill MP, Brotchie JM, Johnston TH, Waterhouse BD, Kortagere S. Schneider JS, et al. Exp Neurol. 2021 Jan;335:113514. doi: 10.1016/j.expneurol.2020.113514. Epub 2020 Oct 22. Exp Neurol. 2021. PMID: 33141071
Mild cognitive impairment is present in a number of neurodegenerative disorders including Parkinson's disease (PD). Mild cognitive impairment in PD (PD-MCI) often manifests as deficits in executive functioning, attention, and spatial and working memory …
Mild cognitive impairment is present in a number of neurodegenerative disorders including Parkinson's disease (P …
GM1 Ganglioside Modifies alpha-Synuclein Toxicity and is Neuroprotective in a Rat alpha-Synuclein Model of Parkinson's Disease.
Schneider JS, Aras R, Williams CK, Koprich JB, Brotchie JM, Singh V. Schneider JS, et al. Sci Rep. 2019 Jun 10;9(1):8362. doi: 10.1038/s41598-019-42847-x. Sci Rep. 2019. PMID: 31182727 Free PMC article.
These results extend prior positive results in MPTP models, are consistent with the results of a small clinical study of GM1 in PD patients that showed slowing of symptom progression with chronic use, and argue for the continued refinement and development of GM1 as a potential …
These results extend prior positive results in MPTP models, are consistent with the results of a small clinical study of GM1 in PD patients …
No sex differences in use of dopaminergic medication in early Parkinson disease in the US and Canada - baseline findings of a multicenter trial.
Umeh CC, Pérez A, Augustine EF, Dhall R, Dewey RB Jr, Mari Z, Simon DK, Wills AM, Christine CW, Schneider JS, Suchowersky O. Umeh CC, et al. Among authors: schneider js. PLoS One. 2014 Dec 8;9(12):e112287. doi: 10.1371/journal.pone.0112287. eCollection 2014. PLoS One. 2014. PMID: 25486269 Free PMC article. Clinical Trial.
BACKGROUND: Sex differences in Parkinson disease clinical features have been reported, but few studies have examined sex influences on use of dopaminergic medication in early Parkinson disease. The objective of this study was to test if there are diffe …
BACKGROUND: Sex differences in Parkinson disease clinical features have been reported, but few studies have examined sex influ …
NYX-458 Improves Cognitive Performance in a Primate Parkinson's Disease Model.
Barth AL, Schneider JS, Johnston TH, Hill MP, Brotchie JM, Moskal JR, Cearley CN. Barth AL, et al. Among authors: schneider js. Mov Disord. 2020 Apr;35(4):640-649. doi: 10.1002/mds.27962. Epub 2020 Jan 22. Mov Disord. 2020. PMID: 31967361
BACKGROUND: NYX-458 is a N-methyl-d-aspartate receptor (NMDAR) modulator that enhances synaptic plasticity. Dopaminergic cell loss in Parkinson's disease (PD) leads to NMDAR dysregulation in the cortico-striato-pallidal-thalmo-cortical network and altered pla …
BACKGROUND: NYX-458 is a N-methyl-d-aspartate receptor (NMDAR) modulator that enhances synaptic plasticity. Dopaminergic cell loss in Par
Relationship between Motor Symptoms, Cognition, and Demographic Characteristics in Treated Mild/Moderate Parkinson's Disease.
Schneider JS, Sendek S, Yang C. Schneider JS, et al. PLoS One. 2015 Apr 23;10(4):e0123231. doi: 10.1371/journal.pone.0123231. eCollection 2015. PLoS One. 2015. PMID: 25905783 Free PMC article.
BACKGROUND: Although Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized primarily by motor symptoms, PD patients, at all stages of the disease, can experience cognitive dysfunction. ...METHODS: Cognitive function was ass …
BACKGROUND: Although Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized primarily by mo …
Parkinson's disease: sensory and motor problems in arms and hands.
Schneider JS, Diamond SG, Markham CH. Schneider JS, et al. Neurology. 1987 Jun;37(6):951-6. doi: 10.1212/wnl.37.6.951. Neurology. 1987. PMID: 3587646
Fifteen undemented patients with Parkinson's disease (PD) and 15 age-matched controls were given a battery of tests to assess sensorimotor integration in the arms. ...
Fifteen undemented patients with Parkinson's disease (PD) and 15 age-matched controls were given a battery of tests to …
118 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page